...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith got a licensing upgrade.

RVXOT, Zenith's ,July 31 2021, Financials  Page 14 states: 

"Zenith agreed to pay Resverlogix for its proportionate share of rental payments and operating costs (for a laboratory and offices that Resverlogix shares with Zenith) of an estimated $0.2 million and $0.1 million, respectively, for the next twelve months." 

Do you understand the estimated shared expenses to be $300K per month or annually? You seem to indicate $200K to $250K per quarter. 

 

Koo

Share
New Message
Please login to post a reply